16 results
8-K
EX-99.2
GOSS
Gossamer Bio Inc
14 May 19
Gossamer Bio Announces First Quarter 2019 Financial Results
7:31am
to deliver innovative, patient-focused new medicines for underserved therapeutic areas 4 assets in clinical development, targeting various indications … preclinical targets for future development Our People: Deeply experienced leadership team with proven track record of developing innovative clinical
8-K
EX-99.1
GOSS
Gossamer Bio Inc
6 May 24
Entry into a Material Definitive Agreement
7:31am
that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s
DRS
GOSS
Gossamer Bio Inc
11 Oct 18
Draft registration statement
12:00am
in determining the extent to which new drugs will be covered. Some third-party payors may requirepre-approval of coverage for new or innovative … innovative payment and service delivery models to lower Medicare and Medicaid spending.
At this time, we are unsure of the full impact that the Affordable
10-K
uwhjim
22 Mar 19
Annual report
4:45pm
424B4
19gho15 4qrk
8 Feb 19
Prospectus supplement with pricing info
4:40pm
S-1
bii x2pzm
21 Dec 18
IPO registration
4:39pm
DRS/A
hnl58uzbqaj3x2y4mq
29 Nov 18
Draft registration statement (amended)
12:00am
S-1/A
rd3e90s70wvbe
23 Jan 19
IPO registration (amended)
4:39pm
DEF 14A
3ggfp
30 Apr 19
Definitive proxy
4:04pm
- Prev
- 1
- Next